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of said complications is increasing
may be true, but this again had nothing
to do with the integrity of previous es-
timates made in a good faith effort to
study results. I hope this clarifies any
question in the readers’ minds as to
the intention of my statements regard-
ing this issue.
Daniel J. DiBardino, MD
Chief Resident in Cardiac Surgery
Brigham and Woman’s Hospital and
Children’s Hospital Boston Program
Boston, Mass
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MICHAEL E. DEBAKEY
The obituary of Dr DeBakey was
very interesting.1 One of Dr DeBakey’s
pioneering efforts does need special
emphasis. By using autologous saphe-
nous vein(s), on November 23, 1964,2
DeBakey performed the first human
coronary artery bypass graft surgery
to the left anterior descending coronary
artery in an asymptomatic patient after
myocardial infarction.
Shahbudin H. Rahimtoola, MB,
FRCP, DSc (Hon)
LACþUSC Medical Center
Cardiology
Los Angeles, Calif
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Letters to the Editor
The JourPULMONARYARTERIAL
HYPERTENSION AND
CONGENITAL HEART
DISEASE: TARGETED
THERAPIES AND
OPERABILITY
To the Editor:
We read with great interest the case
report of Hoetzenecker and colleagues1
of a patient with severe pulmonary arte-
rial hypertension associated with an
atrial septal defect and the beneficial
effect of bosentan, which allowed for
closure of the defect. This is a very inter-
esting topic that raises a lot of cont-
roversies in the field of pulmonary
arterial hypertension associated with
congenital heart disease.2
I would like to comment on the he-
modynamic data presented in Table 1.
Total pulmonary resistance at baseline
is calculated at 460 dynes $ s1 $ cm5,
but pulmonary vascular resistance,
taking the mean left atrial pressure in
the calculation, which is commonly
done in congenital heart disease,
would give a value of 311 dynes $
s1 $ cm5 or 3.9 Wood units, which
is very close to a value of 3 Wood units
considered as totally safe for surgical
repair. If we calculate the ratio of pul-
monary to systemic blood flow (Qp/
Qs), we have a value of 2.7, which is
also considered a value that allows
for repair.
Moreover, when we look at the data
during the nitric oxide testing, these
values reach a pulmonary vascular resis-
tance of 1.78 Wood units or 142 dynes $
s1 $ cm5, the Qp/Qs is 3.25, and the
pulmonary arterial saturation reaches
84.5%. All these values are consistent
with a reactive pulmonary vascular
bed and are values that will clearly al-
low closure of the shunt for a congenital
cardiologist.3,4 It would be of interest
also to report the ratio of pulmonary
over systemic vascular resistance, as
a ratio<0.33 indicates good prognosis
after closure of the shunt.4
Maybe the authors used the defini-
tion of reactivity used for other forms
of pulmonary arterial hypertension, al-nal of Thoracic and Cardiovascular Surlowing for the use of calcium channel
blockers, but this may not be applied
for the evaluation of operability in pa-
tients with congenital heart disease.
Why did the authors think that this par-
ticular patient required bosentan treat-
ment based on these measurements? If
we look at the data after treatment and
just before repair, the hemodynamic
does not look much better than with
nitric oxide, as the pulmonary vascular
resistance is 2.6 Wood units or 205
dynes $ s1 $ cm5 and Qp/Qs is 2.24.
Why was the patient considered oper-
able with these values but not before?
If this is based only on mPAP, I would
suggest the authors should discuss the
fact that mLAP also had a significant
decrease.
Finally, if we analyze the measure-
ment 8 months after repair, the pulmo-
nary vascular resistance is 4.2 and the
mean pulmonary arterial pressure is
35 mm Hg—still not normal. We
clearly hope that these values will re-
main at these levels and not rise again
in the coming month, as the outcome,
at least in pediatric patients with recur-
rent pulmonary hypertension after re-
pair, is dismal, as shown recently by
Haworth and colleagues.5
Maurice Beghetti, MD
Cecile Tissot, MD
Pediatric Cardiology Unit
Department of the Child and
Adolescent
Children’s University Hospital of
Geneva
Geneva, Switzerland
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was<0.33 (in the patient, this ratio
was 0.11), a threshold pediatric cardi-
ologists have labeled as a criterion
conveying a good prognosis after clo-
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We thank Dr Beghetti and col-
leagues for their thoughtful comments
regarding the hemodynamic evalua-
tion and further management of our re-
cent case of atrial septal defect (ASD).1
The management of patients with a de-
gree of pulmonary vascular disease
prior to shunt closure has been a matter
of debate. In addition, recent studies
demonstrating the efficacy of oral
vasodilators in pulmonary vascular
disease associated with congenital
systemic-to-pulmonary shunts2,3 have
fueled an uncertainty of vasodilator
pretreatments prior to shunt closure.
Despite optimized medical treat-
ment with diuretics, antibiotics, and
oral anticoagulant over 4 months since
the first medical contact, our patient
was severely dyspneic, with elevated
atrial pressures, a pro–brain natriuretic
peptide serum level of above 4000 pg/
mL, and a dramatically limited 6-min-
ute walking distance (6-MWD) of 150
m. In fact, based on the hemodynamic
assessment alone, the patient was ad-
mitted to the surgical ward for ASD
closure. However, surgeons refused
the operation based on the patient’s
overall clinical profile and frailty. A
10-month treatment with bosentan on
top of supportive treatment with di-
uretics and anticoagulation effectively
decreased shunt flow and lowered
pulmonary vascular resistance by 140
dynes $ s1 $ cm5 and markedly de-
creased atrial pressures, biomarkers,
and 6-MWD in the presence of
a mild arterial desaturation.
We do agree with the discussants
that taking into account left atrial pres-
plete hemodynamic responder status
in adults were not fulfilled in this
case.5 Because hemodynamic testing
is a routine procedure in adult pulmo-
nary vascular centers, we do rely on
these data in the absence of firm evi-
dence indicating their uselessness in
adults with congenital heart disease.
Moreover, children are usually exam-
ined under general sedation/anesthe-
sia. For these and other reasons, it is
evident that the hemodynamic re-
sponse pattern in children is different
from that in adults6 and that hemody-
namic criteria in children may not ap-
ply to elderly adults. Furthermore,
later assessments after surgery in the
patient under discussion illustrated
a degree of persistent pulmonary vas-
cular disease with a pulmonary arterio-
lar resistance of 530 dynes $ s1 $ cm5,
despite active treatment with bosen-
tan.1
The main value of this report is to
provoke discussion, because due to its
single case nature, surgery in the ab-
sence of bosentan cannot be repeated.
We submit that our invasive proce-
dure was based on an integrative
clinical and hemodynamic approach
and guided by numbers, rather than
the reverse. Controlled data to guide
a ‘‘targeted treatment-and-repair’’
strategy in adult patients with congen-
ital heart disease are needed.
Konrad Hoetzenecker, MDa
Hendrik J. Ankersmit, MDa
Irene M. Lang, MDb
Departments of aCardiothoracic
Surgery and
bCardiology Medical University of
Vienna, Austria
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QUALITYOF LIFE IN PATIENTS
WITH PROSTHESIS–PATIENT
MISMATCH
To the Editor:
I read with interest the article by
Moon and colleagues1 and thank the
authors for their contribution to the
continued debate on the issue of pros-
thesis–patient mismatch (PPM).
PPM is an important topic in current
cardiac surgery, and there are several
discrepancies and contrasting publica-
tions about the effect of PPM on
postoperative outcome.2,3 Some of
these controversies are discussed in
the accompanying counterpoint article
by Dr Feindel.4 In their work Moon
and colleagues1 provide important in-
sight into the management of aortic
valve replacement (AVR) with bio-
prostheses in patients older than 70
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